MNPR Monopar Therapeutics

Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference

Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference

WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a one-on-one fireside chat with Jason McCarthy, PhD, Senior Managing Director of Equity Research, at the Maxim Group’s Healthcare Virtual Conference on Tuesday June 20, 2023 at 1:30pm ET.

Fireside Chat Details:

Date: June 20, 2023

Time: 1:30 pm ET

Location: Virtual Conference

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: .

CONTACT:  

Monopar Therapeutics Inc.

Investor Relations  

Kim R. Tsuchimoto  

Chief Financial Officer  

Follow Monopar on social media for updates: 

Twitter:   LinkedIn:



EN
14/06/2023

Underlying

MNPRMonopar Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Monopar Therapeutics

 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation...

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (“EASL”) International Liver Congre...

April 29, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results an...

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments. “2024 was a productive year for Monopar, with the in-licensing of ALXN1840, the initiation of two first-in-human radiopharma Phase 1 clinical trials, and the strengthening of our ...

March 31, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offe...

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addition to the shares sold in the registered offering,...

December 20, 2024 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Announces First Patient Dosed with its Novel Therapeutic Radio...

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involv...

December 5, 2024 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar to Present at the 36th Annual Piper Sandler Healthcare Confere...

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference. Presentation Details: Date: December 5, 2024Time: 10:30-10:55 am Eastern Time Location: Lotte New York ...

December 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch